What Virogin Biotech does

Virogin Biotech is a clinical-stage immuno-oncology company developing oncolytic virotherapy and mRNA vaccine candidates for the treatment of cancer. Founded in Canada in 2015 by William Jia and Chris Huang, the company is headquartered in Richmond, British Columbia, with a Shanghai office and active clinical operations in Australia, China, and the United States. The company employs between 51 and 100 people and is led by co-founder and CEO Chris Huang (also Chairman and Executive Director) and co-founder and CSO William Jia, with Ronghua Zhao serving as Chief Medical Officer since 2017 and as Executive Director from April 2026. Its end therapeutic focus is on patients with advanced solid tumors, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, pancreatic, breast, and prostate cancers.

Virogin's core technology is a proprietary Transcription & Translation Dual Regulation (TTDR) backbone applied to herpes simplex virus type 1 (HSV-1), combining tumor-associated promoters for transcriptional control with multiple microRNA-binding sites governing the neurovirulence factor ICP34.5 for translational control, which restricts viral replication to tumor cells. The platform supports armed oncolytic virus candidates — most notably VG161 (HSV-1 expressing IL-12, IL-15, and IL-15Rα) currently in clinical studies for intrahepatic cholangiocarcinoma and hepatocellular carcinoma, and VG2025 (non-attenuated HSV-1 expressing IL-12 and IL-15/RA payloads) in Phase I for advanced solid tumors — as well as an mRNA vaccine platform addressing HPV-related and HER2-expressing tumors. The company's Prime-Boost Approach combines intratumoral OV administration with mRNA vaccine boosting to overcome the immunosuppressive tumor microenvironment and elicit systemic anti-tumor immunity, and is supported by process development and manufacturing capability for both virus- and mRNA-based therapeutics.

The business model is licensing- and partnership-driven. As a clinical-stage developer, Virogin aims to bring therapeutic candidates to early clinical proof-of-concept and then out-license to biotech or pharmaceutical partners that wish to utilize its oncolytic virus or mRNA platforms. The company has raised approximately $204 million across multiple funding rounds from 2015 through 2021, with institutional investors including China Life Healthcare Fund, CDH Investments, CMG-SDIC Capital, Korea Investment Partners, Panlin Capital, and others. Pricing details are not publicly disclosed, and the company has not announced any product commercialization, licensing transaction, or revenue stream to date.

Name

Virogin Biotech

Legal name

Virogin Biotech Canada Ltd

Website

https://virogin.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Virogin Biotech is a clinical-stage Canadian immuno-oncology company developing armed oncolytic HSV-1 therapies (VG161, VG2025) and mRNA cancer vaccines for patients with advanced solid tumors, intending to out-license candidates to pharma partners after early proof-of-concept.

Ownership category

akta.pro rank

Product category

Oncolytic Virus Immunotherapy & mRNA Cancer Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industries

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Oncolytic virotherapy
• MRNA cancer vaccines
• Immuno-oncology therapeutics
• Clinical-stage biopharmaceuticals
• Prime-boost immunotherapy

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Licensing and Partnership Revenue: Virogin aims to bring impactful therapeutic candidates to early clinical proof-of-concept for licensing. The company is committed to expanding its pipeline through strategic collaborations with research institutes, biotech, and big pharma companies utilizing their oncolytic virus platform and mRNA platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Virogin Biotech is a clinical-stage immuno-oncology company developing novel oncolytic virotherapy products and mRNA-based cancer vaccines. Its lead candidates VG161 and VG2025 are engineered oncolytic herpes simplex virus type 1 (HSV-1) therapeutics armed with immunomodulatory cytokine payloads (IL-12, IL-15, IL-15Rα) that selectively replicate in tumor cells and stimulate anti-tumor immunity. The company brings candidates to early clinical proof-of-concept for licensing to pharmaceutical partners and pursues collaborations around its proprietary oncolytic virus and mRNA vaccine platforms.

Product overview

Virogin Biotech is a clinical-stage immuno-oncology company developing a portfolio of oncolytic virotherapy products and mRNA vaccines for cancer treatment. The core products include VG161 (oncolytic HSV-1 with IL-12/IL-15/IL-15Rα payloads) and VG2025 (oncolytic HSV-1 with IL-12/IL-15/RA payloads), both leveraging the proprietary Transcription & Translation Dual Regulation (TTDR) backbone. These are combined with an mRNA vaccine platform through the company's Prime-Boost Approach, which uses intratumoral oncolytic virus administration to overcome immunosuppressive tumor microenvironment followed by mRNA vaccine boosting to amplify systemic anti-tumor immunity.

Differentiator

Problem solved

Functional benefit

Products and services

• VG161 Oncolytic herpes simplex virus type 1 (HSV-1) armed with multiple immunomodulatory transgenes (IL-12, IL-15, IL-15Rα) using Virogin's proprietary Transcription & Translation Dual Regulation (TTDR) backbone. Selectively replicates in tumor cells, stimulates the tumor microenvironment, and is in clinical studies for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and other solid tumors; intended ultimately for licensing to pharmaceutical partners.
• VG2025 Non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads for the treatment of advanced solid tumors, currently in Phase I clinical trials.
• Prime-Boost Approach Heterologous prime-boost immunotherapy strategy that combines intratumoral oncolytic virus administration with mRNA vaccine boosting to overcome the immunosuppressive tumor microenvironment and induce robust humoral and cellular anti-tumor immune responses.
• mRNA Vaccine Platform mRNA vaccine technology platform for cancer treatment, including HPV-related cancer and HER2-expressing tumor vaccine candidates utilizing APC-targeting antigens to boost systemic anti-tumor immunity when combined with Virogin's oncolytic virus candidates.

Quantifiable outcome

• Phase I trial demonstrated safety and tolerability of VG2025 in advanced solid tumors
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Research InstitutionscoreStrategic or Co-development PartnerVirogin welcomes opportunities to collaborate with research institutes that wish to utilize their oncolytic virus platform and mRNA platform. Contact: [email protected]
• Biotech CompaniescoreStrategic or Co-development PartnerVirogin is committed to expanding its pipeline through strategic collaborations with biotech companies for co-development of therapeutic candidates.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerVirogin aims to bring impactful therapeutic candidates to early clinical proof-of-concept for licensing to big pharma companies that wish to utilize their oncolytic virus platform and mRNA platform.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• PsiOxus Therapeutics: Clinical-stage immuno-oncology company developing the enadenotucirev-based oncolytic adenovirus platform (e.g., NG-641, NG-350A), often in combinations with immuno-modulatory payloads. Direct OV peer with a comparable 'armed virus' strategy.
• Replimune Group: Clinical-stage immuno-oncology company developing a proprietary oncolytic virus platform (RP1, RP2, RP3) using an enhanced-potency HSV backbone. Closely comparable to Virogin as a similarly sized, clinical-stage OV developer pursuing combinations with systemic IO agents.
• Oncorus: Clinical-stage biotech developing oncolytic virus immunotherapies including an HSV-1-based platform (ONCR-177) armed with IL-12 and other immunomodulators. Closely comparable to Virogin in modality (HSV-1 OV with cytokine payloads) and stage.
• DNAtrix: Clinical-stage developer of oncolytic viruses (DNX-2401/tasadenoturev, an adenovirus-based OV) for brain tumors and other solid tumors. Direct OV peer, though focused on different indications and viral backbones.
• Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies (e.g., TBio-6517, an RANTES/IL-15-armed OV) and tumor-infiltrating lymphocyte (TIL) therapies. Comparable as a small clinical-stage OV developer pursuing combination IO strategies.
• Targovax: Clinical-stage immuno-oncology company developing oncolytic virus platforms (e.g., ONCOS-102, an adenovirus-based OV armed with GM-CSF) for solid tumors. Direct OV peer with a similar 'armed OV' scientific approach.
• CG Oncology: Clinical-stage immuno-oncology company developing oncolytic virus therapy (cretostimogene grenadenorepvec) primarily for bladder cancer. Comparable as a clinical-stage OV developer, with a more advanced late-stage program but narrower indication focus.

Broad incumbents

• Amgen: Owns Imlygic (talimogene laherparepvec / T-VEC), the only FDA-approved oncolytic virus therapy, via its BioVex acquisition. Comparable as the established incumbent whose Imlygic benchmark Virogin's OV candidates must differentiate against.
• Moderna: Commercial-stage mRNA therapeutics company with a significant oncology pipeline (e.g., mRNA-4157/V940 with Merck, INT) including personalized neoantigen cancer vaccines. Comparable as the dominant incumbent in the mRNA cancer vaccine space that Virogin's mRNA platform must compete against for partnerships and talent.

Regional players

• Transgene: European (France-based) clinical-stage biotech developing oncolytic viruses (e.g., TG6002, BT-001) and therapeutic cancer vaccines. Comparable as an OV developer but headquartered in Europe, serving as a regional peer rather than direct North American competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/viroginbiotech/?originalSubdomain=ca

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virogin Biotech